Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697385 | 1.00 | ALDH1A1 (0.41) | ALDH1A1RNPEPTSHRCTSSCTSK | |
| SCHEMBL11053310 | 0.86 | RNPEP (0.39) | ALDH1A1RNPEPTSHRCTSSCTSK | |
| SCHEMBL11053305 | 0.86 | RNPEP (0.39) | ALDH1A1RNPEPTSHRCTSSCTSK | |
| SCHEMBL9114022 | 0.82 | CTSB (0.50) | ALDH1A1CTSSCTSKCTSBFOLH1 | |
| SCHEMBL8722926 | 0.81 | ALDH1A1 (0.38) | ALDH1A1RNPEP | |
| SCHEMBL3923432 | 0.81 | CTSB (0.49) | ALDH1A1CTSSCTSKCTSBFOLH1 | |
| SCHEMBL3911006 | 0.78 | — | — | |
| SCHEMBL56437 | 0.78 | HDAC7 (0.35) | ALDH1A1TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL3911009 | 0.78 | — | — | |
| SCHEMBL3819093 | 0.76 | CTSK (0.56) | ALDH1A1TSHRCTSSCTSKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | claimed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | claimed |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230372308-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | VANDERBILT UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11752138-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | VANDERBILT UNIVERSITY (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| CN-109996797-B | 1H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | 美国政府健康及人类服务部 | 2022-07-22 | — | — | CN | disclosed |
| US-20220220078-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-07-14 | — | — | US | disclosed |
| WO-1998048768-A1 | COMPOSITIONS FOR COSMETIC APPLICATIONS | MEDLOGIC GLOBAL CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0326067-A2 | Use of cyclophilin as an anti-inflammatory and immunomodulatory agent | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372308-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | XDH, GLS, LDHA | ALDH1A1 121/4885RNPEP 1907/4885TSHR 4483/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | ALDH1A1 1200/4885RNPEP 599/4885TSHR 2282/4885 |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NPR1 | ALDH1A1 985/4885RNPEP 556/4885TSHR 2823/4885 |
| US-11752138-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | XDH, GLS, LDHA | ALDH1A1 76/4885RNPEP 1936/4885TSHR 4406/4885 |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | ALDH1A1 10/4885RNPEP 513/4885TSHR 4202/4885 |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | ALDH1A1 709/4885RNPEP 989/4885TSHR 2677/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | ALDH1A1 717/4885RNPEP 395/4885TSHR 4871/4885 |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, NPR1 | ALDH1A1 936/4885RNPEP 621/4885TSHR 2870/4885 |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | ALDH1A1 709/4885RNPEP 989/4885TSHR 2677/4885 |
| US-20220220078-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | LDHB, LDHA, PDHA1 | ALDH1A1 10/4885RNPEP 513/4885TSHR 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.